Medrio Launches Enhanced Channel Partner Program to Facilitate Success for CROs

Share Article

The Medrio Partner Program will enable our partner Contract Research Organizations (CROs) with the ability to quickly and easily offer Medrio’s solutions to fulfill increased customer demand for our industry-leading cloud-based EDC and eSource solutions.

Medrio logo
"The Medrio Partner Program will enable our CRO Partners to deploy Medrio’s EDC and eSource (Direct Data Capture) solution within a few short weeks, reducing the overall timelines and costs of clinical trials." Steve Geffon, Chief Commercial Officer, Medrio

Medrio, the leading provider of eClinical technology for early-phase pharma, medical device, and diagnostics clinical trials, has rolled out several significant updates to the Medrio Partner Program, a collaborative effort equipping contract research organizations (CROs) with a range of critical resources to accelerate study start-up timelines and improve data quality. The updates are the next phase of Medrio’s efforts to facilitate success for their CRO customers by delivering top-tier support, business success, and a smooth eClinical experience.

“CROs are looking towards next-generation technology for a fast, flexible and intuitive solution designed to accelerate study timelines and improve data quality,” commented Steve Geffon, Chief Commercial Officer of Medrio. “The Medrio Partner Program will enable our CRO Partners to deploy Medrio’s EDC and eSource (Direct Data Capture) solution within a few short weeks, reducing the overall timelines and costs of clinical trials.”

As part of the upgrade, Medrio has released numerous new benefits for CRO Partners. These benefits come in addition to existing resources such as sponsor referrals and product roadmap insights, and include:

  • Resource portal – On-demand portal feature summaries, case studies, bid defense support decks, and other assets empower CROs to highlight their success and pursue sponsor business.
  • Self-running demos – CRO Partners can now access pre-recorded, shareable demonstrations of the Medrio system, including quick builds, end-user overviews, and more.
  • Partner Training – Training on the Medrio suite of services including EDC, Direct Data Capture, eConsent, and ePRO, as well as how to market and sell Medrio to study sponsors.

Medrio has also sharpened its focus on delivering value tailored to clinical pharmacology units (CPUs). The company’s fully-compliant integrated EDC and eSource platforms enable these clinical trial sites to minimize data entry errors, accelerate study startup, reduce source data verification, and improve patient recruitment in early phase clinical trials. Medrio’s solutions have been found to yield up to a 50% reduction in data management costs.

“Medrio has always had a strong, mutually-beneficial relationship both with the CRO market and with designated sites focused on early phase clinical trials,” commented Mike Novotny, founder and CEO of Medrio. “With Medrio’s recent shifts, we’re taking that relationship to the next level.”

Please contact strategicalliances(at)medrio.com or visit the Medrio website to learn more about the Medrio Partner Program.

About Medrio
Medrio is the leading provider of eClinical technology for early-phase pharma, device, and diagnostics clinical trials. Founded in 2005, the company's cloud-based EDC, Direct Data Capture, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 600 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit http://www.medrio.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicholas O'Brien
Visit website